

**HCV TREATMENT & CARE IN VULNERABLE POPULATIONS:  
CHALLENGES, OPPORTUNITIES & FUTURE DIRECTIONS**

**NOVEMBER 7<sup>TH</sup> - 8<sup>TH</sup> 2013**

**ROOM: O'CONNOR SALON**

**VICTORIA PARK SUITES (377 O'CONNOR STREET). OTTAWA, CANADA**

<b>FINAL AGENDA</b>	
<b>DAY 1 – Thursday, November 7<sup>th</sup></b>	
8:15 – 9:00	<b>Registration/Coffee</b>
9:00 – 9:15	<b>Welcoming Remarks from the Assistant Deputy Minister</b> Dr. Judith Bossé, Assistant Deputy Minister, Public Health Agency of Canada
9:15 – 9:30	<b>Introduction &amp; Overview of Workshop</b> <ul style="list-style-type: none"> <li>• <b>Objectives of Agenda &amp; Workshop</b></li> </ul> Mr. Bob Walsh, Canadian Society for International Health
9:30 – 10:00	<b>WHO Response to Viral Hepatitis: WHO Framework for Global Action &amp; WHO's role in promoting hepatitis treatment</b> <ul style="list-style-type: none"> <li>• <b>WHO Response to Viral Hepatitis: The Global Hepatitis Network</b></li> <li>• <b>WHO Viral Hepatitis Strategy Axis 4 (screening, care, and treatment)</b></li> </ul> Dr. Stefan Wiktor, World Health Organization (WHO)
10:00 – 10:30	<b>Overview of PHAC Hepatitis C Prevention and Control Efforts in Canada</b> <ul style="list-style-type: none"> <li>• <b>Public health interventions to reduce the pool of undiagnosed infections: challenges and opportunities</b></li> <li>• <b>Linkage to prevention, treatment, care and support: challenges and opportunities</b></li> </ul> Dr. Tom Wong, Public Health Agency of Canada <b>**Open Discussion**</b>
10:30 – 10:45	<b>Coffee Break</b>
<b>Session A: Overview of HCV Treatment: Where are we now?</b>	
10:45 – 11:05	<b>Clinical Management: Treatment of HCV Mono-infection</b> <ul style="list-style-type: none"> <li>• <b>Current &amp; Emerging Therapies</b></li> <li>• <b>Best Practices &amp; Clinical Practice Guidelines</b></li> </ul> Dr. Curtis Cooper, The Ottawa Hospital

11:05 – 11:25	<p><b>Enhancing HCV testing and linkage to care, United States</b></p> <ul style="list-style-type: none"> <li>• Overview of HCV, HCV/HIV Epidemiology</li> <li>• Access to HCV Care &amp; Support</li> </ul> <p>Dr. Kiren Mitruka, Centers for Disease Control and Prevention</p>
11:25 – 11:45	<p><b>Modeling prevalence of chronic HCV and sequelae by birth cohort: a useful tool for testing policies, priority populations and cost-benefit analysis</b></p> <ul style="list-style-type: none"> <li>• Testing Policies &amp; Priority Populations</li> </ul> <p>Dr. Ping Yan, The Public Health Agency of Canada</p>
11:45 – 12:05	<b>**Chaired Discussion: Ian Culbert, Canadian Public Health Association</b>
12:05– 13:00	<p><b>Lunch: The Global HCV Network (12:30 – 12:50)</b></p> <ul style="list-style-type: none"> <li>• Overview of Network Activities</li> <li>• Proposed Future Directions</li> </ul> <p>Ms. Janet Hatcher Roberts, CSIH Open Discussion</p>
	<b>Session B: HCV &amp; Co-infections</b>
13:00 – 13:20	<p><b>Clinical Management of HCV/HIV Co-infection</b></p> <ul style="list-style-type: none"> <li>• Best Practices &amp; Clinical Practice Guidelines</li> </ul> <p>Dr. Sunil Varghese, The Ottawa Hospital</p>
13:20 – 13:40	<p><b>Meaningful Involvement of People Living with HCV/HIV Co-infection in KTE, Capacity Building and Research</b></p> <p>Ms. Colleen Price, Community Member, Advocate, Junior Researcher</p>
13:40 – 14:00	<b>**Chaired Discussion: Paul Sutton, Canadian Treatment Action Council</b>
14:00 – 14:15	<b>Coffee Break</b>
	<b>Session C: A Spotlight on Priority Populations</b>
14:15 – 14:30	<p><b>Case Study #1: Barriers to Care: Access, treatment, management, and care strategies with recent and active Drug Users</b></p> <p>Dr. Julie Bruneau, Département de Médecine Familiale, Université de Montréal</p>
14:30 – 14:45	<p><b>Case Study #2: Barriers to Care: Treatment, management, and care strategies: Lessons from the TB World</b></p> <p>Dr. Ryan Cooper, University of Alberta</p>
14:45 – 15:00	<p><b>Case Study #3: Progress and challenges to care: Treatment, management, and care strategies in China</b></p> <p>Dr. Fuqiang Cui, CDC China</p>
15:00 – 15:20	<b>**Chaired Discussion: Mary Maclean, Sandy Hill Community Health Centre</b>
15:20 – 15:40	<b>Concluding Remarks – End of Day 1</b>

<b>DAY 2 – Friday, November 8<sup>th</sup></b>	
8:30 – 9:00	<b>Arrival/Coffee</b>
9:00 – 9:15	<b>Outline of the day</b> Mr. Bob Walsh, Canadian Society for International Health
	<b>Session D: Integrating Strategies from HIV/AIDS Community</b>
9:15 – 9:35	<b>Applying HIV Model to Viral Hepatitis – Treatment as Prevention</b> Dr. Mark Hull, BC Centre for Excellence in HIV/AIDS
9:35 – 9:55	<b>Applying HIV Model to HCV Drug Process</b> Mr. Allan Miranda, Janssen Inc.
9:55 – 10:15	<b>**Chaired Discussion: Don Sutherland, Consultant</b>
10:15 – 10:30	<b>Coffee Break</b>
10:30 – 11:30	<b>Group Exercise</b> Group 1: Treatment as Prevention Model – Scale Up Possibilities Group 2: HCV Treatment & Care – The New Frontier Group 3: HIV/AIDS Programming & Applicability to HCV
11:30 – 12:00	<b>Report Back from Work Groups: Presentations &amp; Discussion</b>
12:00 – 13:00	<b>Lunch</b>
13:00 – 14:00	<b>Group Exercise</b> Group 1: Treatment Research/Clinical Trials Group 2: Promoting Access to Testing & Linkages to Treatment Group 3: Awareness & Knowledge of Treatment
14:00 – 14:30	<b>Report Back from Work Groups: Presentations &amp; Discussion</b>
14:30 – 15:00	<b>Overview of Workshop, Next Steps, and Concluding Remarks</b> <b>**Chaired Discussion**</b> <b>Concluding Remarks – End of Day 2</b>

*Funding for this Workshop is being provided by Public Health Agency of Canada & AbbVie*